SPRYCELÂ® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to GleevecÂ®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase